Assay Service for assessing ADME properties and in vivo PK properties with the selected vendor.
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 75N98026Q01083ENAMINEYSINC in this department, oldest first.
- Aug 25, 2026 · this noticePre-solicitation
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
Assay Service for assessing ADME properties and in vivo PK properties with the selected vendor. The Section on Medicinal Chemistry (SMC) develops new molecular entities with implications in improving health and treatment for various metabolic and alcohol associated diseases. To assess the translational potential of novel molecular entities, which would allow us to make decisions to proceed with the compounds for further development we utilize multiple derisking assays. These assays comprise of both cell-based (in vitro) testing and then eventually in mice to assess pharmacokinetic parameters t… (show all)
o see if the drug is orally available. Request to procure Chemical Reagent (Assay) Development & Laboratory Testing Service SMC to produce grouped ADME assays and perform a Pharmacokinetic study in C57BL6 mice. By including the Caco-2 Permeability Assay in our ADME evaluation it'll accurately predict the oral absorption potential of our compounds. This well-established in vitro model closely mimics the human intestinal epithelium, providing critical insights into a compound�s passive diffusion, active transport, and efflux processes, such as those mediated by P-glycoprotein (P-gp). The data generated from this assay are vital for informing structure-activity relationship (SAR) optimization, improving compound permeability, and reducing transporter-related liabilities that could hinder bioavailability. CACO and MDCKR assays allow to know the brain penetrance of the compounds. hERG assays allow to know if the compounds will show cardiac toxicity. The plasma stability and binding show how the compounds behave in bodily fluids. Finally, the best compounds then undergo testing in mice to know if they can be given orally and thus have translational potential in human testing. These assays are integral to the work of section on medicinal chemistry at NIAAA as these enable to progress compounds for further development as therapeutics in metabolic and alcohol use disorders.
Who won similar work
3 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same product/service code (PSC) 6505.
Single-winner award sizes (3): middle half $82K to $470K, median $137K; range $28K to $804K.
| Winner | Awards | Value | Last |
|---|---|---|---|
| VECTOR BIOMED INC. | 1 | $804K | Dec 2, 2024 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC · $PACB · $159.3M | 1 | $137K | Nov 19, 2024 |
| 10X GENOMICS, INC. · $TXG · $616.9M | 1 | $28K | Dec 20, 2024 |
Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.
- $PACB reported $159.3M revenue (12 months to Jun 30, 2026). The median single-winner award in these 3 past awards, $137K, is under 0.1% of that. SEC filing
- $TXG reported $616.9M revenue (12 months to Jun 30, 2026). The median single-winner award in these 3 past awards, $137K, is under 0.1% of that. SEC filing
One award's total value against one year of revenue; many awards are paid over several years.
- Dec 20, 202410X GENOMICS, INC.$28K65--Xenium Add On KitMateriality: <0.01% of $TXG revenue (Low) SEC
- Dec 2, 2024VECTOR BIOMED INC.$804KServices for the Production and Stability Testing of Clinical Grade Lentiviral VectorNo listed company matched (Materiality N/A)
- Nov 19, 2024PACIFIC BIOSCIENCES OF CALIFORNIA, INC$137K65--Revio SPRQ reagent kitMateriality: 0.09% of $PACB revenue (Low) SEC
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 3 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- No corporate PAC money from them to the overseeing committees since 2024
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 2 of the past winners are listed companies
- 0 insider buys and 5 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name, including the subsidiaries a company lists in its SEC filings. A company we could not match shows no market rows; that is a miss, not a finding.